Humacyte

Q2 FY2026 EarningsQ3 FY26 results beat consensus across key metrics: total revenue of $1.03M exceeded the $0.77M expectation by 33.51%, driven by a 151% QoQ surge in Symvess sales. Net loss of -$15.54M was significantly narrower than the -$21.65M consensus, aided by reduced R&D spending and non-cash derivative gains. While the GAAP gross margin of -39.01% missed the expected 70.67% due to significant idle capacity overhead, management’s Q4 revenue guidance—anticipating at least a doubling of Q3 sales—suggests accelerating commercial momentum.